News, technologies, and the latest trends in diagnostics all in one place

Visit us at Medica 2024 in Düsseldorf!

The second week of November is usually very busy in Düsseldorf, Germany. Hotels and guesthouses are running at full speed, restaurants are bursting at the seams, and the whole city is transformed into a lively human anthill. Locals have become accustomed to the city coming alive whenever international trade fairs are held at the Düsseldorf Exhibition Centre.

One of the largest events in the field of medical technology and healthcare worldwide is the Medica fair, which opens its doors to almost 100,000 visitors in the second week of November. This already significantly affects the normal functioning of the city with 650,000 inhabitants. Add another 5,000 exhibitors from 70 countries, and it becomes clear that Düsseldorf in November turns into a key destination for many healthcare companies.

Careful preparation as the key to success

For us at BioVendor Group , this fair is the highlight of the event season, and this year will be no different. Fitting all BioVendor Group companies into a shared exhibition space and creating a welcoming environment for hundreds of meetings with new and existing business partners, customers, and suppliers is no easy task. These four days are always preceded by months of careful preparation.

We want to showcase the best and latest from our portfolio of immunological and molecular diagnostics products to the professional public. We aim to present the results of our colleagues' work, supported not only by teams from development, production, and quality control, but also by other supporting departments essential for the successful launch of a product to the market.

And what have we prepared for you this year?

The main "drivers" will again be the key projects CLIA, MBA, and NGS, developed in synergy by the various companies of the BioVendor Group . In line with our long-term vision of accessible, reliable, and personalized diagnostics, we will introduce the groundbreaking immunological biomarker MxA, which plays a key role in distinguishing between bacterial and viral infections. This represents a significant advancement in personalized treatment, uniquely available on three platforms: CLIA, ELISA, and POCT.

What lies behind the ever-growing CLIA portfolio, and where the entire process of development, production, quality control, and application-support services actually takes place, will be revealed in our brand-new video, “BioVendor Group CLIA: ready for your discoveries.”

A number of other product news and innovations from the companies BioVendor Research & Diagnostic Products , TestLine Clinical Diagnostics s.r.o. , ViennaLab Diagnostics , DIAsource ImmunoAssays? S.A. and BioVendor MDx will be personally presented to you by our colleagues at the shared BioVendor Group booth:

Michal ?teffl , Head of International Sales at TestLine Clinical Diagnostics s.r.o. ([email protected]):

“The market segment newcomer – MxA, will for sure be one of the hot topics. As a key player in the immune response to viral infections, it helps differentiate viral from bacterial Infections. We will also be delighted to introduce our brand-new micro-array kits for the diagnosis of liver and gastrointestinal autoimmune diseases.”

Anna Kolouchová , Business Development Manager at BioVendor MDx ([email protected]):

“We will present our NGS fastGEN technology, offering rapid and accurate genetic analysis, which enables efficient cancer diagnostics. Our fastGEN BCR::ABL1 cancer kit specifically detects fusion genes associated with leukemia, supporting early diagnosis and treatment management. I’ll be delighted to meet you and discuss these innovations, including our bioinformatics solution GENOVESA for seamless data interpretation and reporting.”

PETER KERCKX , International Sales & Marketing Manager & Business Manager RIA at DIAsource ImmunoAssays? S.A. ([email protected]):

“DiaSource is proud to announce the addition of a new rapid test (POCT) and its respective reader to our portfolio. These products complete our panel with additional technologies and interesting parameters in the fields of Women’s Health, Tumor Markers, Drugs of Abuse, Infectious Diseases, Cardiac Markers. We are also launching a series of new antibodies in the fields of Alzheimer's disease, Cardiac markers, Diabetes and Fertility. These antibodies have proven to be reliable raw materials in the manufacturing of immunoassays such as CLIA, ELISA, FIA, POCT.

I would also like to mention the new version of our ELISA reader, washer and shaker. Our instruments now have a modern, sophisticated look, with an improved user interface designed to simplify the laboratories operations and streamline data management. Our ELISA reader meets the latest IVDR standards.“

Lenka Sochorová , Sales Manager at BioVendor Research & Diagnostic Products ([email protected]):

“BioVendor RnD offers an extensive portfolio of ELISA kits for both research and diagnostic applications. In addition to our high-quality ELISA kits, we provide high-purity proteins and a broad range of antibodies. Our latest addition is the MxA Point-of-Care-Test, designed for the rapid differentiation between bacterial and viral infections.”

Anna Malolepszy , NGS Product Specialist at ViennaLab Diagnostics ([email protected]):

“Our R&D team at ViennaLab is working around the clock on several developments that will soon be launched on the market. To learn more about the upcoming SMA RealFast Assay, comprehensive OncNGS (liquid biopsy (cfDNA) NGS solution), 16S Microbiome + ITS NGS Assay, and our existing portfolio join our team at Medica 2024!”

Eva Svobodová , Business Director at BioVendor - Laboratorní medicína a.s. ([email protected]):

“We are looking forward to this year's Medica Congress and meeting with our business partners, as well as discovering the innovations that will be presented. We believe that together we will find new opportunities and ideas for our collaboration.”

Come see for yourself and stop by our booth A92 in hall 3. We look forward to seeing you!